Please login to the form below

Not currently logged in
Email:
Password:

Increlex

This page shows the latest Increlex news and features for those working in and with pharma, biotech and healthcare.

EMA publishes European drug shortage details

EMA publishes European drug shortage details

EMA publishes European drug shortage details. First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... The two other drugs with shortages assessed by the EMA are Ipsen's Increlex (mecasermin), for people with a growth disorder

Latest news

  • North-South divide?

    As such, treatments for high need, orphan conditions have been approved with costs per QALY potentially above £40, 000 (46, 000), like mecasermin (Increlex) for growth failure in children and nelarabine

  • Reaching new heights

    A compelling video illustrated the case of the first UK patient diagnosed with Severe Primary IGFD and treated with Recombinant human insulin-like growth factor-I (rhIGF-I), Increlex. ... 75 per cent were 'considerably more confident' in using rhIGF-1

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics